Literature DB >> 804439

Studies in vivo of cobra factor and murine C3.

M B Pepys.   

Abstract

The effect of the isolated C3-cleaving factor (CoF) of cobra venom on murine C3 in vivo and in vitro was studied. Optimal quantities of 100-200 units (0.5 minus 1.0 mg) of CoF per kg administered to mice by intraperitoneal injection in divided doses caused plasma C3 levels to fall to less than 5 per cent of normal from 1 to at least 4 days afterwards. Passive anti-CoF serum promptly abrogated the in vivo plasma C3 depletion, and under optimal conditions C3 levels reached 50 per cent of normal after approximately 15 hours. Injection of as little as 20 mug per mouse of CoF in saline induced a precipitating anti-CoF antibody response which prevented subsequent depletion of plasma C3 by CoF. The in vivo half-life of 125I-labelled CoF in normal mice estimated by whole body elimination and clearance from the blood was 24 hours. The presence in vivo of antibodies to CoF caused rapid clearance from the blood and elimination of 125I-labelled CoF, and also localization of some CoF in the spleen, liver and kidneys.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 804439      PMCID: PMC1445818     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  10 in total

1.  ANTIGEN-ANTIBODY CROSSED ELECTROPHORESIS.

Authors:  C B LAURELL
Journal:  Anal Biochem       Date:  1965-02       Impact factor: 3.365

2.  MOUSE BETA-1C-GLOBULIN: PRODUCTION OF ANTISERUM AND CHARACTERIZATION IN THE COMPLEMENT REACTION.

Authors:  M R MARDINEY; H J MUELLER-EBERHARD
Journal:  J Immunol       Date:  1965-06       Impact factor: 5.422

3.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

4.  Role of complement in induction of the allergic response.

Authors:  M B Pepys
Journal:  Nat New Biol       Date:  1972-05-31

5.  Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions.

Authors:  C G Cochrane; H J Müller-Eberhard; B S Aikin
Journal:  J Immunol       Date:  1970-07       Impact factor: 5.422

6.  Complement studies in membrano-proliferative glomerulonephritis.

Authors:  D K Peters; A Martin; A Weinstein; J S Cameron; T M Barratt; C S Ogg; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1972-07       Impact factor: 4.330

7.  Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.

Authors:  M Ballow; C G Cochrane
Journal:  J Immunol       Date:  1969-11       Impact factor: 5.422

8.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

9.  Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.

Authors:  J A Charlesworth; D G Williams; E Sherington; P J Lachmann; D K Peters
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

10.  Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses.

Authors:  M B Pepys
Journal:  J Exp Med       Date:  1974-07-01       Impact factor: 14.307

  10 in total
  23 in total

1.  Classical and alternative pathway complement activation are not required for reactive systemic AA amyloid deposition in mice.

Authors:  Winston L Hutchinson; Jeff Herbert; Marina Botto; Mark B Pepys
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

2.  Depletion of complement has distinct effects on the primary and secondary antibody responses to a conjugate of pneumococcal serotype 14 capsular polysaccharide and a T-cell-dependent protein carrier.

Authors:  Samuel T Test; Joyce K Mitsuyoshi; Yong Hu
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Complement activation in acetaminophen-induced liver injury in mice.

Authors:  Rohit Singhal; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2012-02-07       Impact factor: 4.030

4.  The effect of complement depletion on lung clearance of bacteria.

Authors:  G N Gross; S R Rehm; A K Pierce
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

5.  Complement in the induction of IgE antibody formation.

Authors:  M B Pepys; W D Brighton; B E Hewitt; D E Bryant; J Pepys
Journal:  Clin Exp Immunol       Date:  1977-03       Impact factor: 4.330

6.  IgM response and resistance to ascites tumor growth.

Authors:  J L Subiza; J Coll; R Alvarez; M Valdivieso; E G de la Concha
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

7.  Trypanosoma musculi infections in normocomplementemic, C5-deficient, and C3-depleted mice.

Authors:  J A Jarvinen; A P Dalmasso
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

8.  The role of complement in experimental bullous pemphigoid.

Authors:  Z Liu; G J Giudice; S J Swartz; J A Fairley; G O Till; J L Troy; L A Diaz
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  Complement-independence of the acute-phase production of serum amyloijd P-component (SAP) in mice.

Authors:  M B Pepys; S L Rogers
Journal:  Br J Exp Pathol       Date:  1980-04

10.  Serum protein concentrations during Schistosoma mansoni infection in intact and T-cell deprived mice. I. The acute phase proteins, C3 and serum amyloid P-component (SAP).

Authors:  M B Pepys; M L Baltz; R Musallam; M J Doenhoff
Journal:  Immunology       Date:  1980-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.